Biopreservation Market to Accelerate at 18.2% CAGR, Reaching Revenues of US$24.5 Billion by 2033
December 20, 2024 06:43 ET
|
Research and Markets
Dublin, Dec. 20, 2024 (GLOBE NEWSWIRE) -- The "Biopreservation Market: Global Forecast by Product, Application, Countries and Company Analysis" report has been added to ResearchAndMarkets.com's...
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis
December 19, 2024 08:30 ET
|
PRISM MarketView
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™
Thought Leadership & Innovation Foundation Celebrates the Launch of Autism Knowledge Gateway
December 10, 2024 10:02 ET
|
Thought Leadership & Innovation Foundation
Thought Leadership & Innovation Foundation launches Autism Knowledge Gateway, an AI-powered platform designed to connect families, clinicians & researchers
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings
December 09, 2024 16:05 ET
|
OncoCyte Corporation
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings – January 13-16, 2025, San Francisco, CA
Dr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts General Hospital (MGH), Joins Klotho Neurosciences’ Scientific Advisory Board
December 09, 2024 11:00 ET
|
Klotho Neurosciences, Inc.
Dr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts General Hospital (MGH), Joins Klotho Neurosciences’ Scientific Advisory Board
Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study
December 04, 2024 16:15 ET
|
OncoCyte Corporation
Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study
VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Post-Operative Inflammation Following Cataract Surgery
December 04, 2024 11:07 ET
|
VivaVision Biotech, Ltd.
VVN461, a non-steroidal dual JAK1/TYK2 immunomodulator, achieves primary endpoint, demonstrating statistical and clinical efficacy compared to vehicle in treating post-operative inflammation following...
Former Merck USA President Joins Klotho Neurosciences’ Board of Directors
December 03, 2024 11:00 ET
|
Klotho Neurosciences, Inc.
Former Merck USA President Joins Klotho Neurosciences’ Board of Directors
Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus
December 03, 2024 08:30 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus
Halberd Update on WatchDawg® PTSD Treatment
December 02, 2024 08:00 ET
|
Halberd Corp.
Halberd Update on WatchDawg® PTSD Treatment